CAS: 13551-92-3 - 3-(2-nitro-1H-imidazol-1-yl)propane-1,2-diol
Formula:C6H9N3O4
InChI:InChI=1S/C6H9N3O4/c10-4-5(11)3-8-2-1-7-6(8)9(12)13/h1-2,5,10-11H,3-4H2
InChI key:InChIKey=NUGLIYXAARVRPQ-UHFFFAOYSA-N
SMILES:O=N(=O)C1=NC=CN1CC(O)CO
- Synonyms:
- 1,2-Propanediol, 3-(2-nitro-1H-imidazol-1-yl)-
- 1,2-Propanediol, 3-(2-nitroimidazol-1-yl)-
- 1-(2,3-Dihydroxypropyl)-2-nitro-1H-imidazole3-(2-Nitroimidazol-1-yl)-1,2-propanediol
- 3-(2-Nitro-1H-imidazol-1-yl)-1,2-propanediol
- 3-(2-Nitroimidazol-1-yl)-1,2-propanediol
- Demethylmisonidazole
- Desmethylmisonidazole
- Dhpni
- NSC 261036
- Ro 5-9963
- See more synonyms
- SR 1530 (imidazole)
- Sr 1530
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol REF: IN-DA006YUXCAS: 13551-92-3 | - - - | To inquire | Thu 23 Jan 25 | |
3-(2-Nitro-imidazol-1-yl)-propane-1,2-diol REF: 54-OR97711CAS: 13551-92-3 | 95+% | 696.00 € | Thu 30 Jan 25 | |
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol REF: 10-F219024CAS: 13551-92-3 | 95.0% | To inquire | Tue 04 Feb 25 | |
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol REF: 3D-NAA55192CAS: 13551-92-3 | Min. 95% | - - - | Discontinued product |
Ref: IN-DA006YUX
Undefined size | To inquire |
Estimated delivery in United States, on Thursday 23 Jan 2025
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol
CAS:13551-92-3
Purity:
95.0%
Color and Shape:
Solid
Molecular weight:
187.15499877929688
Ref: 10-F219024
250mg | To inquire |
Estimated delivery in United States, on Tuesday 4 Feb 2025
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol
CAS:13551-92-3
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol is a cytotoxic agent that inhibits the synthesis of DNA. It binds to the …
Formula:
C6H9N3O4
Purity:
Min. 95%
Molecular weight:
187.16 g/mol
Ref: 3D-NAA55192
1g | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |